Method of treating a methionine-dependent cancer
AssigneeAgency for Science, Technology and Research
InventorsZhenxun Wang, Wai Leong Tam, Lian Yee Yip, Ying Swan Ho, Zhengwei Wu, Bing Lim
Life of this patent
Estimating the term…
Abstract
The present specification relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.
Claims6
A method of treating cancer or reducing the risk of recurrence of cancer in a subject who has previously had an anti-cancer therapy, the method comprising the step of administering an inhibitor of methionine adenosyltransferase 2A (MAT2A) to the subject to inhibit proliferation of a tumor initiating cell or eliminate a tumor initiating cell in the cancer, wherein the tumor initiating cell expresses MAT2A, cluster of differentiation 166 (CD166), serine hydroxymethyltransferase 2 (SHMT2) and methylthioadenosine phosphorylase (MTAP), thereby treating or reducing the risk of recurrence of cancer in the subject.
Dependencies are inferred from the claim text.